Provided by Tiger Trade Technology Pte. Ltd.

Unicycive Therapeutics, Inc.

4.70
+0.14503.19%
Post-market: 4.700.00000.00%19:30 EDT
Volume:862.71K
Turnover:4.05M
Market Cap:130.78M
PE:-3.01
High:4.81
Open:4.61
Low:4.57
Close:4.55
52wk High:8.74
52wk Low:3.93
Shares:27.86M
Float Shares:27.23M
Volume Ratio:0.89
T/O Rate:3.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5585
EPS(LYR):-1.6715
ROE:-101.07%
ROA:-40.59%
PB:2.46
PE(LYR):-2.81

Loading ...

Eledon Pharmaceuticals Q2 Net Loss Widens on Warrant Liability Changes

Reuters
·
Aug 14

Unicycive Therapeutics Price Target Cut to $20.00/Share from $22.00 by B. Riley Securities

Dow Jones
·
Aug 13

B. Riley Securities Reaffirms Their Buy Rating on Unicycive Therapeutics (UNCY)

TIPRANKS
·
Aug 13

B. Riley Adjusts Price Target on Unicycive Therapeutics to $20 From $22, Maintains Buy Rating

MT Newswires Live
·
Aug 13

Unicycive Therapeutics Inc : Guggenheim Cuts Target Price to $25 from $37

THOMSON REUTERS
·
Aug 13

Inovio Q2 Net Loss Narrows on Warrant Gain, Lower Costs

Reuters
·
Aug 13

Unicycive Rises on Narrower Quarterly Loss

Reuters
·
Aug 13

Unicycive Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Unicycive Therapeutics Q2 Net Loss Narrows on Warrant Liability Change

Reuters
·
Aug 12

Unicycive Therapeutics Q2 EPS USD -0.06

THOMSON REUTERS
·
Aug 12

Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

THOMSON REUTERS
·
Aug 12

Unicycive Therapeutics - Q2 Net Loss was $1.70 Mln or $0.06 Per Share

THOMSON REUTERS
·
Aug 12

Unicycive Therapeutics Q2 EPS $(0.06) Beats $(0.34) Estimate

Benzinga Earnings
·
Aug 12

Unicycive Net Loss Widens 147% to USD 14.55 Million in FY26 First Half

Reuters
·
Aug 12

Unicycive Therapeutics Inc Expected to Post a Loss of 34 Cents a Share - Earnings Preview

Reuters
·
Aug 10

Unicycive Therapeutics Publishes Corporate Presentation on Kidney Disease Drug Pipeline

Reuters
·
Aug 01

Unicycive Therapeutics Posts Corporate Presentation on Kidney Disease Pipeline, Lead Hyperphosphatemia Drug OLC

Reuters
·
Jul 07

Unicycive Therapeutics Gets Complete Response Letter from FDA on Resubmitted Oxylanthanum Carbonate NDA

Reuters
·
Jul 06

Unicycive Therapeutics Reports Preliminary Q2 2026 Cash Position

TIPRANKS
·
Jul 02

Unicycive Therapeutics price target lowered to $13 from $18 at Benchmark

TIPRANKS
·
Jul 01